The Latest Cardiac and Vascular News
MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha is a cardiac electrophysiologist who brings to Milestone over thirty years of […]
– Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR – – HR changes occurred within 5 minutes and were sustained for 60 minutes – – Data presented at AHA Scientific Sessions 2021 – MONTREAL and CHARLOTTE, N.C., Nov. 15, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical […]
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update. “We continue to make meaningful progress across our etripamil PSVT program. We’ve […]
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update. “We continue to work closely with our existing clinical trial sites, […]
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal spray for the Reduction of Ventricular Rate in patients experiencing Atrial fibrillation and rapid ventricular rate (AFib-RVR), […]
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a clinical and corporate update. “We are keenly focused on executing on our etripamil development […]
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2020 and provided a clinical and corporate update. “We remain on track to reopen enrollment in the pivotal Phase 3 […]
MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2020 and provided a clinical and corporate update. “With the benefit of having completed our first Phase 3 clinical trial and […]
MONTREAL and CHARLOTTE, N.C., April 16, 2019 /PRNewswire/ — Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular conditions, today announced the appointment of Paul Edick as Chairman of its Board of Directors. Mr. Edick currently serves as Chairman and Chief Executive Officer of Xeris Pharmaceuticals, a publicly traded specialty pharmaceutical company […]
MONTREAL and CHARLOTTE, N.C., April 4, 2019 /PRNewswire/ — Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular indications, today announced the appointment of Michael Tomsicek to its Board of Directors. Mr. Tomsicek is currently the Chief Financial Officer of CRISPR Therapeutics, a biopharmaceutical company focused on developing gene-based medicines. In addition […]
